



Please send this referral via fax: 6382 3800  
or email: [bookings@envisionmi.com.au](mailto:bookings@envisionmi.com.au) and  
we will contact you with an appointment.

**Patient Details**

Patient Name \_\_\_\_\_

DOB \_\_\_\_\_ Phone \_\_\_\_\_

Address \_\_\_\_\_

**Examination Required**

**PET-CT** (No out of pocket cost for Medicare eligible PET-CT scans)

- Solitary Pulmonary Nodule (61523)
- Non-Small Cell Lung Cancer (61529)

**Hodgkins or NHL**

- Initial Staging (61620)
- First-line therapy response (61622)
- Restaging (61628)
- Second-line therapy response (61632)

**Head/Neck**

- Staging (61598)
- Residual (61604)

**Met SCC Cervical LN**

- Unknown Primary (61610)

Malignant Brain Tumour (61538)

Oesophageal/GOJ (61577)

Colorectal Carcinoma (61541)

Ovarian Carcinoma (61565)

**Breast Carcinoma**

- Staging (locally advanced) (61524)
- Metastatic/recurrent (61525)

**Carcinoma of Uterine Cervix**

- Primary Staging (61571)
- Restaging (61575)

**Sarcoma** (Excluding GIST)

- Initial Staging (61640)
- Residual/Recurrent (61646)

Melanoma (61553)

Other FDG PET

Gallium 68 PSMA

(Includes CT Abdomen/Pelvis)

Gallium 68 Octreotate

- GEP Neuroendocrine Tumour (61647)

**Please tick if associated Diagnostic CT is required**

- CT Chest/Abdomen/Pelvis
- CT Abdomen/Pelvis
- CT Chest
- CT Head
- CT Neck \_\_\_\_\_
- CT Other \_\_\_\_\_

Nuclear Medicine

Ultrasound

X-Ray

Bone Densitometry

**MRI**

**Medicare Eligible**

- Rectal Ca Staging (63476)
- Ca Cervix Figo ≥1B Staging Pelvis (63470)
- Ca Cervix Figo ≥1B Staging Abdo & Pelvis (63473)
- MRCP (63482)
- Liver with Primovist (Metastatic Colorectal Ca) (64545)
- Liver with Primovist (Known or suspected HCC & confirmed chronic liver disease & liver function Child-Pugh A or B & hepatic lesion >10mm (64546)

**Liver**

- (63545)
- (63546)
- Primovist (63496)

**Cervix**

- Ca Cervix (63470)
- Ca Cervix and Abdo (63473)

**Rectum**

- Ca Rectal (63476)

**Non Medicare Eligible**

- Upper Abdomen
- Pelvis

**Clinical Details / Queries**

Creatinine if available \_\_\_\_\_

Previous Imaging at \_\_\_\_\_ (please advise)

- Allergies
- Please do not upload to My Health Record

**Requesting Practitioner**

Signature \_\_\_\_\_


Date \_\_\_\_\_

**Report**

Electronic

Fax

Mail



**Hours of Operation**

Monday to Friday 8.30am – 5.00pm

Saturday 8.00am – 1.00pm

(MRI is available out of hours Mon – Thurs and weekends)

**PET-CT REBATEABLE ITEMS**

**Solitary Pulmonary Nodule (61523)**

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.

**Breast Carcinoma - Staging (locally advanced) (61524)**

Whole body 18F-FDG PET study where the patient is referred by a specialist or consultant physician, performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy.

**Breast Carcinoma - Metastatic / recurrent (61525)**

Whole body 18F-FDG PET study, where the patient is referred by a specialist or consultant physician, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy.

**Non-Small Cell Lung Cancer (61529)**

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.

**Malignant Brain Tumour (61538)**

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.

**Colorectal Carcinoma (61541)**

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.

**Melanoma (61553)**

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered for active therapy.

**Ovarian Carcinoma - Recurrence (61565)**

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.

**Carcinoma of Uterine Cervix - Primary Staging (61571)**

Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.

**Carcinoma of Uterine Cervix - Restaging (61575)**

Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.

**Oesophageal/GOJ (61577)**

Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.

**Head/Neck - Staging (61598)**

Whole body FDG PET study performed for the staging of biopsy proven newly diagnosed or recurrent head and neck cancer.

**Head/Neck - Residual (61604)**

Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.

**Met SCC Cervical LN - Unknown Primary (61610)**

Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.

**Hodgkins or NHL - Initial Staging (61620)**

Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).

**Hodgkins or NHL - 1st Line Therapy (61622)**

Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).

**Hodgkins or NHL - Restaging (61628)**

Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma)

**Hodgkins or NHL Lymphoma - Post 2<sup>nd</sup> Line Chemotherapy (61632)**

Whole body FDG PET study to assess response to secondline chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).

**Sarcoma - Initial Staging (61640)**

Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.

**Sarcoma - Residual/Recurrent (61646)**

Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.

**Neuroendocrine Tumour (61647)**

Whole body <sup>68</sup>Ga-DOTA-peptide PET study if:  
(a) a gastro-entero-pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or  
(b) both:  
(i) a surgically amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and  
(ii) the study is for excluding additional disease sites

